Pro-Hdl may be available in the countries listed below.
Ingredient matches for Pro-Hdl
Lovastatin
Lovastatin is reported as an ingredient of Pro-Hdl in the following countries:
- India
International Drug Name Search
Thursday, September 29, 2016
Ziagen
abacavir sulfate
Dosage Form: tablet,film coated; oral solution
FULL PRESCRIBING INFORMATION
WARNING: RISK OF HYPERSENSITIVITY REACTIONS, LACTIC ACIDOSIS, AND SEVERE HEPATOMEGALY
Hypersensitivity Reactions: Serious and sometimes fatal hypersensitivity reactions have been associated with Ziagen® (abacavir sulfate).
Hypersensitivity to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) fever, (2) rash, (3) gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain), (4) constitutional (including generalized malaise, fatigue, or achiness), and (5) respiratory (including dyspnea, cough, or pharyngitis). Discontinue Ziagen as soon as a hypersensitivity reaction is suspected.
Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.
Regardless of HLA-B*5701 status, permanently discontinue Ziagen if hypersensitivity cannot be ruled out, even when other diagnoses are possible.
Following a hypersensitivity reaction to abacavir, NEVER restart Ziagen or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.
Reintroduction of Ziagen or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of hypersensitivity to abacavir therapy, can result in serious or fatal hypersensitivity reactions. Such reactions can occur within hours [see Warnings and Precautions (5.1)].
Lactic Acidosis and Severe Hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including Ziagen and other antiretrovirals [see Warnings and Precautions (5.2)].
Indications and Usage for Ziagen
Ziagen Tablets and Oral Solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection.
Additional important information on the use of Ziagen for treatment of HIV-1 infection:
Ziagen is one of multiple products containing abacavir. Before starting Ziagen, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1), Adverse Reactions (6)].
Ziagen Dosage and Administration
- A Medication Guide and Warning Card that provide information about recognition of hypersensitivity reactions should be dispensed with each new prescription and refill.
- To facilitate reporting of hypersensitivity reactions and collection of information on each case, an Abacavir Hypersensitivity Registry has been established. Physicians should register patients by calling 1-800-270-0425.
- Ziagen may be taken with or without food.
Adult Patients
The recommended oral dose of Ziagen for adults is 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily, in combination with other antiretroviral agents.
Pediatric Patients
The recommended oral dose of Ziagen Oral Solution in HIV-1-infected pediatric patients aged 3 months and older is 8 mg/kg twice daily (up to a maximum of 300 mg twice daily) in combination with other antiretroviral agents.
Ziagen is also available as a scored tablet for HIV-1-infected pediatric patients weighing greater than or equal to 14 kg for whom a solid dosage form is appropriate. Before prescribing Ziagen Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow Ziagen Tablets, the oral solution formulation should be prescribed. The recommended oral dosage of Ziagen Tablets for HIV-1-infected pediatric patients is presented in Table 1.
Weight (kg) | Dosage Regimen Using Scored Tablet | Total Daily Dose | |
| AM Dose | PM Dose | ||
| 14 to 21 | ½ tablet (150 mg) | ½ tablet (150 mg) | 300 mg |
| >21 to <30 | ½ tablet (150 mg) | 1 tablet (300 mg) | 450 mg |
| ≥30 | 1 tablet (300 mg) | 1 tablet (300 mg) | 600 mg |
Patients with Hepatic Impairment
The recommended dose of Ziagen in patients with mild hepatic impairment (Child-Pugh score 5 to 6) is 200 mg twice daily. To enable dose reduction, Ziagen Oral Solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe hepatic impairment; therefore, Ziagen is contraindicated in these patients.
Dosage Forms and Strengths
Ziagen Tablets contain 300 mg of abacavir as abacavir sulfate. The tablets are yellow, biconvex, scored, capsule-shaped, film-coated, and imprinted with “GX 623” on both sides.
Ziagen Oral Solution contains 20 mg/mL of abacavir as abacavir sulfate. The solution is a clear to opalescent, yellowish, strawberry-banana-flavored liquid.
Contraindications
Ziagen is contraindicated in patients with:
- previously demonstrated hypersensitivity to abacavir or any other component of the products. NEVER restart Ziagen or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status [see Warnings and Precautions (5.1), Adverse Reactions (6)].
- moderate or severe hepatic impairment [see Dosage and Administration (2.3)].
Warnings and Precautions
Hypersensitivity Reaction
Serious and sometimes fatal hypersensitivity reactions have been associated with Ziagen and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.
HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue Ziagen if hypersensitivity cannot be ruled out, even when other diagnoses are possible.
Important information on signs and symptoms of hypersensitivity, as well as clinical management, is presented below.
Signs and Symptoms of Hypersensitivity: Hypersensitivity to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups.
Group 1: Fever
Group 2: Rash
Group 3: Gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain)
Group 4: Constitutional (including generalized malaise, fatigue, or achiness)
Group 5: Respiratory (including dyspnea, cough, or pharyngitis).
Hypersensitivity to abacavir following the presentation of a single sign or symptom has been reported infrequently.
Hypersensitivity to abacavir was reported in approximately 8% of 2,670 patients (n = 206) in 9 clinical trials (range: 2% to 9%) with enrollment from November 1999 to February 2002. Data on time to onset and symptoms of suspected hypersensitivity were collected on a detailed data collection module. The frequencies of symptoms are shown in Figure 1. Symptoms usually appeared within the first 6 weeks of treatment with abacavir, although the reaction may occur at any time during therapy. Median time to onset was 9 days; 89% appeared within the first 6 weeks; 95% of patients reported symptoms from 2 or more of the 5 groups listed above.
Figure 1. Hypersensitivity-Related Symptoms Reported With ≥10% Frequency in Clinical Trials (n = 206 Patients)
Other less common signs and symptoms of hypersensitivity include lethargy, myolysis, edema, abnormal chest x-ray findings (predominantly infiltrates, which can be localized), and paresthesia. Anaphylaxis, liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, and death have occurred in association with hypersensitivity reactions. In one study, 4 patients (11%) receiving Ziagen 600 mg once daily experienced hypotension with a hypersensitivity reaction compared with 0 patients receiving Ziagen 300 mg twice daily.
Physical findings associated with hypersensitivity to abacavir in some patients include lymphadenopathy, mucous membrane lesions (conjunctivitis and mouth ulcerations), and rash. The rash usually appears maculopapular or urticarial, but may be variable in appearance. There have been reports of erythema multiforme. Hypersensitivity reactions have occurred without rash.
Laboratory abnormalities associated with hypersensitivity to abacavir in some patients include elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia.
Clinical Management of Hypersensitivity: Discontinue Ziagen as soon as a hypersensitivity reaction is suspected. To minimize the risk of a life-threatening hypersensitivity reaction, permanently discontinue Ziagen if hypersensitivity cannot be ruled out, even when other diagnoses are possible (e.g., acute onset respiratory diseases such as pneumonia, bronchitis, pharyngitis, or influenza; gastroenteritis; or reactions to other medications).
Following a hypersensitivity reaction to abacavir, NEVER restart Ziagen or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.
When therapy with Ziagen has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation of Ziagen or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of Ziagen to ensure that the patient did not have symptoms of a hypersensitivity reaction. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of Ziagen.
If hypersensitivity cannot be ruled out, DO NOT reintroduce Ziagen or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.
If symptoms consistent with hypersensitivity are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a hypersensitivity reaction. Make patients aware that a hypersensitivity reaction can occur with reintroduction of Ziagen or any other abacavir-containing product and that reintroduction of Ziagen or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others.
Risk Factor: HLA-B*5701 Allele: Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.
CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n = 1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803). Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.
Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.
Skin patch testing is used as a research tool and should not be used to aid in the clinical diagnosis of abacavir hypersensitivity.
In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision-making. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.
Abacavir Hypersensitivity Reaction Registry: An Abacavir Hypersensitivity Registry has been established to facilitate reporting of hypersensitivity reactions and collection of information on each case. Physicians should register patients by calling 1-800-270-0425.
Lactic Acidosis/Severe Hepatomegaly With Steatosis
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir and other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering Ziagen to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with Ziagen should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).
Immune Reconstitution Syndrome
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including Ziagen. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.
Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.
Fat Redistribution
Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.
Myocardial Infarction
In a published prospective, observational, epidemiological study designed to investigate the rate of myocardial infarction in patients on combination antiretroviral therapy, the use of abacavir within the previous 6 months was correlated with an increased risk of myocardial infarction (MI).1 In a sponsor-conducted pooled analysis of clinical trials, no excess risk of myocardial infarction was observed in abacavir-treated subjects as compared with control subjects. In totality, the available data from the observational cohort and from clinical trials are inconclusive.
As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, and smoking).
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of the labeling:
- Serious and sometimes fatal hypersensitivity reaction. In one study, once-daily dosing of abacavir was associated with more severe hypersensitivity reactions [see Boxed Warning, Warnings and Precautions (5.1)].
- Lactic acidosis and severe hepatomegaly [see Boxed Warning, Warnings and Precautions (5.2)].
- Immune reconstitution syndrome [see Warnings and Precautions (5.3].
- Fat redistribution [see Warnings and Precautions (5.4].
- Myocardial infarction [see Warnings and Precautions (5.5)].
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults:Therapy-Naive Adults: Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with Ziagen 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily compared with zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily from CNA30024 are listed in Table 2.
a This study used double-blind ascertainment of suspected hypersensitivity reactions. During the blinded portion of the study, suspected hypersensitivity to abacavir was reported by investigators in 9% of 324 patients in the abacavir group and 3% of 325 patients in the zidovudine group. | ||
b Ten (3%) cases of suspected drug hypersensitivity were reclassified as not being due to abacavir following unblinding. | ||
Adverse Reaction | Ziagen plus Lamivudine plus Efavirenz (n = 324) | Zidovudine plus Lamivudine plus Efavirenz (n = 325) |
Dreams/sleep disorders | 10% | 10% |
Drug hypersensitivity | 9% | <1%b |
Headaches/migraine | 7% | 11% |
Nausea | 7% | 11% |
Fatigue/malaise | 7% | 10% |
Diarrhea | 7% | 6% |
Rashes | 6% | 12% |
Abdominal pain/gastritis/ | 6% | 8% |
Depressive disorders | 6% | 6% |
Dizziness | 6% | 6% |
Musculoskeletal pain | 6% | 5% |
Bronchitis | 4% | 5% |
Vomiting | 2% | 9% |
Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with Ziagen 300 mg twice daily, lamivudine 150 mg twice daily, and zidovudine 300 mg twice daily compared with indinavir 800 mg 3 times daily, lamivudine 150 mg twice daily, and zidovudine 300 mg twice daily from CNA3005 are listed in Table 3.
Adverse Reaction | Ziagen plus Lamivudine/Zidovudine (n = 262) | Indinavir plus Lamivudine/Zidovudine (n = 264) |
Nausea | 19% | 17% |
Headache | 13% | 9% |
Malaise and fatigue | 12% | 12% |
Nausea and vomiting | 10% | 10% |
Hypersensitivity reaction | 8% | 2% |
Diarrhea | 7% | 5% |
Fever and/or chills | 6% | 3% |
Depressive disorders | 6% | 4% |
Musculoskeletal pain | 5% | 7% |
Skin rashes | 5% | 4% |
Ear/nose/throat infections | 5% | 4% |
Viral respiratory infections | 5% | 5% |
Anxiety | 5% | 3% |
Renal signs/symptoms | <1% | 5% |
Pain (non-site-specific) | <1% | 5% |
Five patients receiving Ziagen in CNA3005 experienced worsening of pre-existing depression compared with none in the indinavir arm. The background rates of pre-existing depression were similar in the 2 treatment arms.
Ziagen Once Daily Versus Ziagen Twice Daily (CNA30021): Treatment-emergent clinical adverse reactions (rated by the investigator as at least moderate) with a greater than or equal to 5% frequency during therapy with Ziagen 600 mg once daily or Ziagen 300 mg twice daily both in combination with lamivudine 300 mg once daily and efavirenz 600 mg once daily from CNA30021 were similar. For hypersensitivity reactions, patients receiving Ziagen once daily showed a rate of 9% in comparison with a rate of 7% for patients receiving Ziagen twice daily. However, patients receiving Ziagen 600 mg once daily, experienced a significantly higher incidence of severe drug hypersensitivity reactions and severe diarrhea compared with patients who received Ziagen 300 mg twice daily. Five percent (5%) of patients receiving Ziagen 600 mg once daily had severe drug hypersensitivity reactions compared with 2% of patients receiving Ziagen 300 mg twice daily. Two percent (2%) of patients receiving Ziagen 600 mg once daily had severe diarrhea while none of the patients receiving Ziagen 300 mg twice daily had this event.
Laboratory Abnormalities: Laboratory abnormalities (Grades 3-4) in therapy-naive adults during therapy with Ziagen 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily compared with zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily from CNA30024 are listed in Table 4.
ULN = Upper limit of normal. | ||
n = Number of patients assessed. | ||
Grade 3/4 Laboratory Abnormalities | Ziagen plus Lamivudine plus Efavirenz (n = 324) | Zidovudine plus Lamivudine plus Efavirenz |
Elevated CPK (>4 X ULN) | 8% | 8% |
Elevated ALT (>5 X ULN) | 6% | 6% |
Elevated AST (>5 X ULN) | 6% | 5% |
Hypertriglyceridemia (>750 mg/dL) | 6% | 5% |
Hyperamylasemia (>2 X ULN) | 4% | 5% |
Neutropenia (ANC <750/mm3) | 2% | 4% |
Anemia (Hgb ≤6.9 gm/dL) | <1% | 2% |
Thrombocytopenia (Platelets <50,000/mm3) | 1% | <1% |
Leukopenia (WBC ≤1,500/mm3) | <1% | 2% |
Laboratory abnormalities in CNA3005 are listed in Table 5.
ULN = Upper limit of normal. | ||
n = Number of patients assessed. | ||
Grade 3/4 Laboratory Abnormalities | Number of Subjects by Treatment Group | |
Ziagen plus Lamivudine/Zidovudine (n = 262) | Indinavir plus Lamivudine/Zidovudine (n = 264) | |
Elevated CPK (>4 x ULN) | 18 (7%) | 18 (7%) |
ALT (>5.0 x ULN) | 16 (6%) | 16 (6%) |
Neutropenia (<750/mm3) | 13 (5%) | 13 (5%) |
Hypertriglyceridemia (>750 mg/dL) | 5 (2%) | 3 (1%) |
Hyperamylasemia (>2.0 x ULN) | 5 (2%) | 1 (<1%) |
Hyperglycemia (>13.9 mmol/L) | 2 (<1%) | 2 (<1%) |
Anemia (Hgb ≤6.9 g/dL) | 0 (0%) | 3 (1%) |
The frequencies of treatment-emergent laboratory abnormalities were comparable between treatment groups in CNA30021.
Pediatric Patients:Therapy-Experienced Pediatric Patients: Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with Ziagen 8 mg/kg twice daily, lamivudine 4 mg/kg twice daily, and zidovudine 180 mg/m2 twice daily compared with lamivudine 4 mg/kg twice daily and zidovudine 180 mg/m2 twice daily from CNA3006 are listed in Table 6.
Adverse Reaction | Ziagen plus Lamivudine plus Zidovudine (n = 102) | Lamivudine plus Zidovudine (n = 103) |
Fever and/or chills | 9% | 7% |
Nausea and vomiting | 9% | 2% |
Skin rashes | 7% | 1% |
Ear/nose/throat infections | 5% | 1% |
Pneumonia | 4% | 5% |
Headache | 1% | 5% |
Laboratory Abnormalities: In Study CNA3006, laboratory abnormalities (anemia, neutropenia, liver function test abnormalities, and CPK elevations) were observed with similar frequencies as in a study of therapy-naive adults (CNA30024). Mild elevations of blood glucose were more frequent in pediatric patients receiving Ziagen (CNA3006) as compared with adult patients (CNA30024).
Other Adverse Events: In addition to adverse reactions and laboratory abnormalities reported in Tables 2, 3, 4, 5, and 6, other adverse reactions observed in the expanded access program were pancreatitis and increased GGT.
Postmarketing Experience
In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of Ziagen. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Ziagen.
Body as a Whole: Redistribution/accumulation of body fat.
Cardiovascular: Myocardial infarction.
Hepatic: Lactic acidosis and hepatic steatosis.
Skin: Suspected Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving abacavir primarily in combination with medications known to be associated with SJS and TEN, respectively. Because of the overlap of clinical signs and symptoms between hypersensitivity to abacavir and SJS and TEN, and the possibility of multiple drug sensitivities in some patients, abacavir should be discontinued and not restarted in such cases.
There have also been reports of erythema multiforme with abacavir use.
Drug Interactions
7.1 Ethanol
Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir causing an increase in overall exposure [see Clinical Pharmacology (12.3)].
7.2 Methadone
The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a study of 11 HIV-1-infected patients receiving methadone-maintenance therapy with 600 mg of Ziagen twice daily (twice the currently recommended dose), oral methadone clearance increased [see Clinical Pharmacology (12.3)]. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C. Studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. Fetal malformations (increased incidences of fetal anasarca and skeletal malformations) and developmental toxicity (depressed fetal body weight and reduced crown-rump length) were observed in rats at a dose which produced 35 times the human exposure, based on AUC. Embryonic and fetal toxicities (increased resorptions, decreased fetal body weights) and toxicities to the offspring (increased incidence of stillbirth and lower body weights) occurred at half of the above-mentioned dose in separate fertility studies conducted in rats. In the rabbit, no developmental toxicity and no increases in fetal malformations occurred at doses that produced 8.5 times the human exposure at the recommended dose based on AUC.
There are no adequate and well-controlled studies in pregnant women. Ziagen should be used during pregnancy only if the potential benefits outweigh the risk.
Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to Ziagen, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.
Nursing Mothers
The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.
Although it is not known if abacavir is excreted in human milk, abacavir is secreted into the milk of lactating rats. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving Ziagen.
Pediatric Use
The safety and effectiveness of Ziagen have been established in pediatric patients 3 months to 13 years of age. Use of Ziagen in these age groups is supported by pharmacokinetic studies and evidence from adequate and well-controlled studies of Ziagen in adults and pediatric patients [see Dosage and Administration (2.2), Clinical Pharmacology (12.3), Clinical Studies (14.2)].
Geriatric Use
Clinical studies of Ziagen did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Overdosage
There is no known antidote for Ziagen. It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.
Ziagen Description
Ziagen is the brand name for abacavir sulfate, a synthetic carbocyclic nucleoside analogue with inhibitory activity against HIV-1. The chemical name of abacavir sulfate is (1S,cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. It has a molecular formula of (C14H18N6O)2•H2SO4 and a molecular weight of 670.76 daltons. It has the following structural formula:
Abacavir sulfate is a white to off-white solid with a solubility of approximately 77 mg/mL in distilled water at 25°C. It has an
Zarontin Solution
Pronunciation: ETH-oh-SUX-i-mide
Generic Name: Ethosuximide
Brand Name: Zarontin
Zarontin Solution is used for:
Controlling absence epilepsy (previously known as petit mal seizures). It may also be used for other conditions as determined by your doctor.
Zarontin Solution is an anticonvulsant. It acts in the brain to reduce the number of absence seizures.
Do NOT use Zarontin Solution if:
- you are allergic to any ingredient in Zarontin Solution or similar medicines
Contact your doctor or health care provider right away if any of these apply to you.
Before using Zarontin Solution:
Some medical conditions may interact with Zarontin Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have liver or kidney disease, lupus, or a blood disorder (eg, porphyria)
- if you have a history of mood or mental problems, including suicidal thoughts or attempts
Some MEDICINES MAY INTERACT with Zarontin Solution. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Zarontin Solution
- Valproic acid because it may affect the amount of Zarontin Solution in your blood
This may not be a complete list of all interactions that may occur. Ask your health care provider if Zarontin Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
How to use Zarontin Solution:
Use Zarontin Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.
- Zarontin Solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Zarontin Solution refilled.
- Take Zarontin Solution by mouth with or without food.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Taking Zarontin Solution at the same time each day will help you remember to take it. Take Zarontin Solution on a regular schedule to get the most benefit from it.
- Continue to take Zarontin Solution even if you feel well. Do not miss any doses.
- If you miss a dose of Zarontin Solution, take it as soon as possible. If it is almost time for you next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Zarontin Solution.
Important safety information:
- Zarontin Solution may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Zarontin Solution with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
- Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Zarontin Solution; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.
- Increasing or decreasing the dose as well as adding or stopping other medicines should be done slowly. Rapidly stopping Zarontin Solution may suddenly make absence seizures worse.
- Zarontin Solution may cause swelling and tenderness of your gums. Brush and floss your teeth on a regular schedule and have regular dental checkups.
- Patients who take Zarontin Solution may be at increased risk for suicidal thoughts or actions. The risk may be greater in patients who have had suicidal thoughts or actions in the past. Watch patients who take Zarontin Solution closely. Contact the doctor at once if new, worsened, or sudden symptoms such as depressed mood; anxious, restless, or irritable behavior; panic attacks; or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.
- Lab tests, including complete blood cell counts, liver function, and kidney function tests, may be performed while you use Zarontin Solution. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
- Zarontin Solution should not be used in CHILDREN younger than 3 years old; safety and effectiveness in these children have not been confirmed.
- PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Zarontin Solution while you are pregnant. Zarontin Solution is found in breast milk. If you are or will be breast-feeding while you use Zarontin Solution, check with your doctor. Discuss any possible risks to your baby.
Possible side effects of Zarontin Solution:
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Diarrhea; dizziness; drowsiness; headache; loss of appetite; nausea; stomach pain; stomach upset; vomiting; weight loss.
Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); increased number of seizures; lupus symptoms (eg, butterfly-shaped rash on the face, joint pain or swelling); new or worsening mood or mental changes (eg, depression); nightmares; red, swollen, blistered, or peeling skin; signs of infection (eg, fever, sore throat); suicidal thoughts or attempts; trouble concentrating; trouble sleeping; unusual bruising, bleeding, or fatigue.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Zarontin side effects (in more detail)
If OVERDOSE is suspected:
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include central nervous system depression (eg, coma with slow, shallow breathing); nausea; vomiting.
Proper storage of Zarontin Solution:
Store Zarontin Solution below 86 degrees F (30 degrees C). Store away from heat, moisture, and light. Do not freeze. Keep Zarontin Solution out of the reach of children and away from pets.
General information:
- If you have any questions about Zarontin Solution, please talk with your doctor, pharmacist, or other health care provider.
- Zarontin Solution is to be used only by the patient for whom it is prescribed. Do not share it with other people.
- If your symptoms do not improve or if they become worse, check with your doctor.
- Check with your pharmacist about how to dispose of unused medicine.
This information is a summary only. It does not contain all information about Zarontin Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Issue Date: February 1, 2012
Database Edition 12.1.1.002
Copyright © 2012 Wolters Kluwer Health, Inc.
More Zarontin resources
- Zarontin Side Effects (in more detail)
- Zarontin Dosage
- Zarontin Use in Pregnancy & Breastfeeding
- Drug Images
- Zarontin Drug Interactions
- Zarontin Support Group
- 4 Reviews for Zarontin - Add your own review/rating
Compare Zarontin with other medications
- Seizures
Wednesday, September 28, 2016
Penicillin G
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Penicillin G
Benzylpenicillin
Benzylpenicillin potassium (a derivative of Benzylpenicillin) is reported as an ingredient of Penicillin G in the following countries:
- Turkey
Benzylpenicillin procaine (a derivative of Benzylpenicillin) is reported as an ingredient of Penicillin G in the following countries:
- United States
Benzylpenicillin sodium (a derivative of Benzylpenicillin) is reported as an ingredient of Penicillin G in the following countries:
- Georgia
International Drug Name Search
Zgesic
Generic Name: acetaminophen and phenyltoloxamine (a seet a MIN oh fen and FEN il toe LOX a meen)
Brand Names: Aceta-Gesic, Acuflex, Alpain, Apagesic, BeFlex, BP Poly-650, Dologesic, Flextra-650, Flextra-DS, Hyflex-650, Hyflex-DS, Lagesic, Major-gesic, Percogesic, Phenagesic, Phenylgesic, Q Flex, Relagesic, RhinoFlex, RhinoFlex 650, Staflex, Vistra, Vitoxapap, Zgesic
What is Zgesic (acetaminophen and phenyltoloxamine)?
Acetaminophen is a pain reliever and a fever reducer.
Phenyltoloxamine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Acetaminophen and phenyltoloxamine is used to treat runny nose, sneezing, and pain or fever caused by the common cold, flu, or seasonal allergies.
Acetaminophen and phenyltoloxamine may also be used for purposes not listed in this medication guide.
What is the most important information I should know about Zgesic (acetaminophen and phenyltoloxamine)?
Do not take this medication without a doctor's advice if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take medicine that contains acetaminophen. Do not use cold medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.
Ask a doctor or pharmacist if it is safe for you to take this medicine if you have liver or kidney disease, diabetes, glaucoma, urination problems, an enlarged prostate, heart disease, high blood pressure, a stomach ulcer, or an overactive thyroid.
Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen. Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP.
What should I discuss with my healthcare provider before taking Zgesic (acetaminophen and phenyltoloxamine)?
You should not take this medication if you are allergic to acetaminophen or phenyltoloxamine. Do not take this medication without a doctor's advice if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take medicine that contains acetaminophen. Do not use acetaminophen and phenyltoloxamine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.
Ask a doctor or pharmacist if it is safe for you to take this medicine if you have:
- liver disease or a history of alcoholism;
kidney disease;
diabetes;
glaucoma;
urination problems;
an enlarged prostate;
heart disease or high blood pressure;
a stomach ulcer; or
an overactive thyroid.
It is not known whether acetaminophen and phenyltoloxamine is harmful to an unborn baby. Do not take this medication without telling your doctor if you are pregnant. Acetaminophen and phenyltoloxamine can pass into breast milk and may harm a nursing baby. Do not take this medication without telling your doctor if you are breast-feeding a baby.
How should I take Zgesic (acetaminophen and phenyltoloxamine)?
Use exactly as directed on the label, or as prescribed by your doctor. Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Cold or allergy medicine is usually taken only for a short time until your symptoms clear up.
One tablet of this medicine may contain up to 650 mg of acetaminophen. Know the amount of acetaminophen in the specific product you are taking.
Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Do not crush, chew, or break an extended-release tablet. Swallow it whole. Breaking the pill may cause too much of the drug to be released at one time.
Call your doctor if your symptoms do not improve, or if you have a fever for longer than 3 days.
This medication can cause unusual results with allergy skin tests. Tell any doctor who treats you that you are taking an antihistamine.
Store at room temperature away from moisture and heat.
What happens if I miss a dose?
Since cold or allergy medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of acetaminophen can be fatal.
The first signs of an acetaminophen overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.
Overdose symptoms may also include feeling very restless, extreme drowsiness, warmth or tingly feeling, or seizure (convulsions).
What should I avoid while taking Zgesic (acetaminophen and phenyltoloxamine)?
This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen. Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP. Avoid becoming overheated or dehydrated during exercise and in hot weather. Phenyltoloxamine can decrease sweating and you may be more prone to heat stroke.
Zgesic (acetaminophen and phenyltoloxamine) side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have a serious side effect such as:
fast, pounding, or uneven heartbeat;
confusion, hallucinations, unusual thoughts or behavior;
severe dizziness, anxiety, restless feeling, nervousness;
urinating less than usual or not at all;
nausea, pain in your upper stomach, itching, loss of appetite, dark urine, clay colored stools, jaundice (yellowing of the skin or eyes); or
easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms.
Less serious side effects may include:
dizziness, drowsiness;
blurred vision;
dry mouth, nose, or throat;
mild stomach pain, constipation; or
problems with memory or concentration.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Zgesic (acetaminophen and phenyltoloxamine)?
Before using this medicine, tell your doctor if you regularly use other medicines that make you sleepy (such as other cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by phenyltoloxamine.
There may be other drugs that can interact with acetaminophen and phenyltoloxamine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
More Zgesic resources
- Zgesic Side Effects (in more detail)
- Zgesic Use in Pregnancy & Breastfeeding
- Zgesic Drug Interactions
- Zgesic Support Group
- 0 Reviews for Zgesic - Add your own review/rating
- Acuflex MedFacts Consumer Leaflet (Wolters Kluwer)
- Acuflex Consumer Overview
- Lagesic Controlled-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Percogesic Consumer Overview
Compare Zgesic with other medications
- Cold Symptoms
- Headache
- Influenza
- Pain
Where can I get more information?
- Your pharmacist can provide more information about acetaminophen and phenyltoloxamine.
See also: Zgesic side effects (in more detail)
Blastoferon
Blastoferon may be available in the countries listed below.
Ingredient matches for Blastoferon
Interferon beta
Interferon beta is reported as an ingredient of Blastoferon in the following countries:
- Argentina
International Drug Name Search
Tuesday, September 27, 2016
Zarontin
Pronunciation: ETH-oh-SUX-i-mide
Generic Name: Ethosuximide
Brand Name: Zarontin
Zarontin is used for:
Controlling absence epilepsy (previously known as petit mal seizures). It may also be used for other conditions as determined by your doctor.
Zarontin is an anticonvulsant. It acts in the brain to reduce the number of absence seizures.
Do NOT use Zarontin if:
- you are allergic to any ingredient in Zarontin or similar medicines
Contact your doctor or health care provider right away if any of these apply to you.
Before using Zarontin:
Some medical conditions may interact with Zarontin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have liver or kidney disease, lupus, or a blood disorder (eg, porphyria)
- if you have a history of mood or mental problems, including suicidal thoughts or attempts
Some MEDICINES MAY INTERACT with Zarontin. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Zarontin
- Valproic acid because it may affect the amount of Zarontin in your blood
This may not be a complete list of all interactions that may occur. Ask your health care provider if Zarontin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
How to use Zarontin:
Use Zarontin as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.
- Zarontin comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Zarontin refilled.
- Take Zarontin by mouth with or without food.
- Taking Zarontin at the same time each day will help you remember to take it. Take Zarontin on a regular schedule to get the most benefit from it.
- Continue to take Zarontin even if you feel well. Do not miss any doses.
- If you miss a dose of Zarontin, take it as soon as possible. If it is almost time for you next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Zarontin.
Important safety information:
- Zarontin may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Zarontin with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
- Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Zarontin; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.
- Increasing or decreasing the dose as well as adding or stopping other medicines should be done slowly. Rapidly stopping Zarontin may suddenly make absence seizures worse.
- Zarontin may cause swelling and tenderness of your gums. Brush and floss your teeth on a regular schedule and have regular dental checkups.
- Patients who take Zarontin may be at increased risk for suicidal thoughts or actions. The risk may be greater in patients who have had suicidal thoughts or actions in the past. Watch patients who take Zarontin closely. Contact the doctor at once if new, worsened, or sudden symptoms such as depressed mood; anxious, restless, or irritable behavior; panic attacks; or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.
- Lab tests, including complete blood cell counts and liver and kidney function tests, may be performed while you use Zarontin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
- Zarontin should not be used in CHILDREN younger than 3 years old; safety and effectiveness in these children have not been confirmed.
- PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Zarontin while you are pregnant. Zarontin is found in breast milk. If you are or will be breast-feeding while you use Zarontin, check with your doctor. Discuss any possible risks to your baby.
Possible side effects of Zarontin:
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Diarrhea; dizziness; drowsiness; headache; loss of appetite; nausea; stomach pain; stomach upset; vomiting; weight loss.
Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); increased number of seizures; lupus symptoms (eg, butterfly-shaped rash on the face, joint pain or swelling); new or worsening mood or mental changes (eg, depression); nightmares; red, swollen, blistered, or peeling skin; signs of infection (eg, fever, sore throat); suicidal thoughts or attempts; trouble concentrating; trouble sleeping; unusual bruising, bleeding, or fatigue.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Zarontin side effects (in more detail)
If OVERDOSE is suspected:
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include central nervous system depression (eg, coma with slow, shallow breathing); nausea; vomiting.
Proper storage of Zarontin:
Store Zarontin at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Keep Zarontin out of the reach of children and away from pets.
General information:
- If you have any questions about Zarontin, please talk with your doctor, pharmacist, or other health care provider.
- Zarontin is to be used only by the patient for whom it is prescribed. Do not share it with other people.
- If your symptoms do not improve or if they become worse, check with your doctor.
- Check with your pharmacist about how to dispose of unused medicine.
This information is a summary only. It does not contain all information about Zarontin. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Issue Date: February 1, 2012
Database Edition 12.1.1.002
Copyright © 2012 Wolters Kluwer Health, Inc.
More Zarontin resources
- Zarontin Side Effects (in more detail)
- Zarontin Use in Pregnancy & Breastfeeding
- Drug Images
- Zarontin Drug Interactions
- Zarontin Support Group
- 4 Reviews for Zarontin - Add your own review/rating
- Zarontin Prescribing Information (FDA)
- Zarontin Advanced Consumer (Micromedex) - Includes Dosage Information
- Zarontin Concise Consumer Information (Cerner Multum)
- Zarontin Monograph (AHFS DI)
- Ethosuximide Prescribing Information (FDA)
- Ethosuximide Professional Patient Advice (Wolters Kluwer)
Compare Zarontin with other medications
- Seizures
Subscribe to:
Comments (Atom)